Sun Pharma to acquire oncology product from Novartis for $175 mn

ACQUIRER

Sun Pharma

ACQUIRER COMPANY TYPE

Listed

INDUSTRY (ACQUIRER)

Healthcare & Life Sciences

 

CITY (ACQUIRER)

Mumbai

COUNTRY (ACQUIRER)

India

 

COMPANY

(Novartis)

COMPANY TYPE

Unlisted

INDUSTRY

Healthcare & Life Sciences

SECTOR

Pharmaceuticals

CITY (TARGET)

Princeton, NJ

COUNTRY (TARGET)

USA

 

 

Publicly listed  Sun Pharmaceutical Industries Ltd is to acquire a branded oncology product, Odomzo, from Novartis for an upfront payment of $175 million and additional milestone payments. Odomzo is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

 

Source:https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-to-acquire-oncology-product-from-novartis-for-175-mn/articleshow/56115035.cms